The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Subscribe To Our Newsletter & Stay Updated
